Innoviva (INVA) Cost of Revenue (2011 - 2026)

Innoviva (INVA) has 6 years of Cost of Revenue data on file, last reported at $15.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 76.51% year-over-year to $15.6 million; the trailing twelve-month figure through Mar 2026 stood at $58.2 million (up 54.38% YoY), and the FY2025 full-year result was $77.4 million, up 111.44% from the prior year.
• Cost of Revenue for Q1 2026 stood at $15.6 million, down from $25.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $25.6 million in Q3 2025 and bottomed at $1.6 million in Q1 2023.
• The 4-year median for Cost of Revenue is $9.0 million (2023), against an average of $10.9 million.
• The widest annual swing landed in 2024, when Cost of Revenue surged 585.69%; it then fell 19.41% in 2025.
• A 4-year view of Cost of Revenue shows it stood at $9.0 million in 2023, then rose by 11.26% to $10.0 million in 2024, then surged by 156.69% to $25.6 million in 2025, then plunged by 39.14% to $15.6 million in 2026.
• The last three Cost of Revenue figures came in at $15.6 million (Q1 2026), $25.6 million (Q3 2025), and $8.1 million (Q2 2025), per Business Quant data.

Peer Comparison